Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Long-Term Investments (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Long-Term Investments readings, the most recent being $56.1 million for Q4 2025.

  • On a quarterly basis, Long-Term Investments changed N/A to $56.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $56.1 million, a N/A change, with the full-year FY2022 number at $29.3 million, down 72.99% from a year prior.
  • Long-Term Investments hit $56.1 million in Q4 2025 for Enanta Pharmaceuticals, up from $42.5 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $115.7 million in Q2 2021 to a low of $5.9 million in Q2 2023.
  • Median Long-Term Investments over the past 5 years was $40.8 million (2022), compared with a mean of $49.6 million.
  • Biggest five-year swings in Long-Term Investments: plummeted 84.97% in 2023 and later skyrocketed 617.59% in 2024.
  • Enanta Pharmaceuticals' Long-Term Investments stood at $88.7 million in 2021, then plummeted by 69.62% to $26.9 million in 2022, then crashed by 78.01% to $5.9 million in 2023, then skyrocketed by 617.59% to $42.5 million in 2024, then soared by 31.86% to $56.1 million in 2025.
  • The last three reported values for Long-Term Investments were $56.1 million (Q4 2025), $42.5 million (Q2 2024), and $5.9 million (Q2 2023) per Business Quant data.